The FDA surprised nearly everyone by rejecting AcelRx Pharmaceuticals' new drug application (NDA) for its pre-programmed, non-invasive, handheld system Zalviso, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain.
The news of the complete response letter (CRL) came about 10pm EDT on 25 July long-after the US markets had...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
